Filing Flows › Sarepta Therapeutics (SRPT) › Pmo Products revenue
Sarepta Therapeutics (SRPT) Pmo Products revenue by quarter
Sarepta Therapeutics' Pmo Products revenue was $240M in Q3 2026 (third quarter 2026), +4% from Q2 2026. Over the last 6 quarters it ranged from $229M (Q1 2026) to $259M (Q4 2025).
| Quarter | Pmo Products revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $240M | +4% | +0.7% |
| Q2 2026 | $231M | +0.9% | -0.3% |
| Q1 2026 | $229M | -12% | — |
| Q4 2025 | $259M | +9% | — |
| Q3 2025 | $239M | +3% | — |
| Q2 2025 | $231M | — | — |
Q3 2026 at a glance
Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Sarepta Therapeutics' Pmo Products revenue?
Sarepta Therapeutics' Pmo Products revenue was $240M in Q3 2026 (third quarter 2026), +4% from Q2 2026.
How has Sarepta Therapeutics' Pmo Products revenue changed?
Over the last 6 quarters it ranged from $229M (Q1 2026) to $259M (Q4 2025).